FINWIRES · TerminalLIVE
FINWIRES

$CPRX

6 stories mentioning CPRX

Every FINWIRES story that references CPRX, newest first.

Sectors

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks declined late Thursday afternoon, with the NYSE Health Care Index decreasing 0.6% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) dropped 2.2%.In corporate news, Entrada Therapeutics (TRDA) shares tumbled 57% after its drug for children with Duchenne muscular dystrophy fell short of analyst expectations in an early-to-mid stage trial, Reuters reported Thursday.Iovance Biotherapeutics (IOVA) shares fell past 13% after the company's Q1 loss narrowed less than expected and revenue missed estimates.Harmony Biosciences (HRMY) shares dropped 5.5% after the company's Q1 earnings and revenue fell short of analysts' estimates.Catalyst Pharmaceuticals (CPRX) shares rose 2.1% after the company agreed to be acquired by Angelini Pharma in a deal with an equity value of about $4.1 billion. The company also said it has reached a settlement agreement with Hetero Labs to resolve patent litigation regarding a proposed generic version of Firdapse.

$CPRX$HRMY$IOVA$TRDA
Sectors

Sector Update: Health Care Stocks Decline in Afternoon Trading

Health care stocks declined Thursday afternoon with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 0.7%.The iShares Biotechnology ETF (IBB) dropped 2.6%.In corporate news, Iovance Biotherapeutics (IOVA) shares fell past 13% after the company's Q1 loss narrowed less than expected and revenue missed estimates.Harmony Biosciences (HRMY) shares dropped 5% after the company's Q1 earnings and revenue fell short of analysts' estimates.Catalyst Pharmaceuticals (CPRX) shares rose 2.2% after the company agreed to be acquired by Angelini Pharma in a deal with an equity value of about $4.1 billion. The company also said it has reached a settlement agreement with Hetero Labs to resolve patent litigation regarding a proposed generic version of Firdapse.

$CPRX$HRMY$IOVA
Research

Oppenheimer Downgrades Catalyst Pharmaceuticals to Market Perform From Outperform

Catalyst Pharmaceuticals (CPRX) has an average rating of overweight and mean price target of $33.83, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $31.23, Change: $+0.71, Percent Change: +2.33%

$CPRX
Sectors

Sector Update: Health Care Stocks Mixed Pre-Bell Thursday

Health care stocks were mixed premarket Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) retreating by 0.1% and the iShares Biotechnology ETF (IBB) advancing 0.1%.Cytokinetics (CYTK) shares fell more than 1% premarket after the company said late Wednesday it priced its upsized public offering of about 9.9 million shares at $71 a piece for gross proceeds of around $700 million.Catalyst Pharmaceuticals (CPRX) stock was gaining over 2% before the opening bell after the company agreed to be acquired by Angelini Pharma in a deal with an equity value of about $4.1 billion. The company also said it has reached a settlement agreement with Hetero Labs to resolve patent litigation regarding a proposed generic version of Firdapse, or amifampridine.Lifestance Health Group (LFST) shares rose 11% after the company reported higher Q1 earnings and revenue.

$CPRX$CYTK$IBB$LFST$XLV
Sectors

Sector Update: Health Care Stocks Softer in Afternoon Trading

Health care stocks were lower Monday afternoon with the NYSE Health Care Index easing 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.2%.The iShares Biotechnology ETF (IBB) shed 0.2%.In corporate news, Eli Lilly (LLY) said Monday it has agreed to acquire Ajax Therapeutics for up to $2.3 billion in cash. The deal includes an upfront payment and subsequent payouts based on the achievement of clinical and regulatory milestones, the company said. Lilly shares were down 0.5%.Organon (OGN) shares jumped 17% after the company agreed to be acquired by India's Sun Pharmaceutical Industries $14 a share in cash, valuing the company at $11.75 billion.Moderna (MRNA) is facing a patent infringement lawsuit from CureVac, which alleged that Moderna's COVID-19 vaccine Spikevax used its proprietary mRNA technology without authorization, Reuters reported Saturday. Moderna shares were falling 3.3%.Catalyst Pharmaceuticals (CPRX) is being considered as a potential acquisition by Italy's Angelini Pharma, Bloomberg reported. Catalyst shares rose past 6%.

$CPRX$LLY$MRNA$OGN
Wire

Market Chatter: Catalyst Pharmaceuticals Draws Interest From Italy's Angelini Pharma

Catalyst Pharmaceuticals (CPRX) is being considered as a potential acquisition by Italy's Angelini Pharma, Bloomberg reported Monday, citing people familiar with the matter.Angelini is working with advisers, and talks are at a preliminary stage with no certainty of a transaction, the sources said.The Italian drugmaker is reviewing other possible targets, while Catalyst may attract interest from other suitors, the report said.Catalyst and Angelini did not immediately reply to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $30.29, Change: $+2.92, Percent Change: +10.67%

$CPRX